Product Highlight - Enhertu

21 Mar 2024
Product Highlight - Enhertu

New indication for:

  • Unresectable or metastatic HER2 low breast cancer
  • Advanced HER2+ gastric or gastroesophageal junction (GEJ) adenocarcinoma 2L treatment

Originally indicated for:

  • Unresectable or metastatic HER2+ breast cancer 2L treatment

2L = second-line; HER2+ = HER2 positive.

Reference:
Enhertu HK prescribing information. March 2023.


DAIICHI SANKYO HONG KONG LIMITED
Tel: (+852) 2868 9079
ASTRAZENECA HONG KONG LIMITED
Tel: (+852) 2420 7388

Related MIMS Drugs